| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adapting a prescreening program to match molecular alterations in over 5,000 patients’ tumors with targeted agents and immunotherapies in early clinical trials over the last 8 years
|
Aguilar, S.
|
|
|
29 |
S6 |
p. vi23
|
artikel
|
| 2 |
A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine
|
Seguin, L.
|
|
|
29 |
S6 |
p. vi29
|
artikel
|
| 3 |
Analysis of changes in the markers of DNA methylation in the process of complex treatment in acute myeloid leukemia in children
|
Rudenko, V.V.
|
|
|
29 |
S6 |
p. vi9
|
artikel
|
| 4 |
A nomogram for the prediction of KRAS mutation in colorectal cancer
|
Xiang, W.
|
|
|
29 |
S6 |
p. vi11-vi12
|
artikel
|
| 5 |
A novel acetylated derivative of vitexin improves the immunogenic profile of breast cancer through tuning miR-20a/MICA Axis
|
Awad, A.R.
|
|
|
29 |
S6 |
p. vi18
|
artikel
|
| 6 |
A novel 4-gene prognostic signature for hypermutated colorectal cancer (CRC)
|
Ge, W.
|
|
|
29 |
S6 |
p. vi11
|
artikel
|
| 7 |
Application of liquid biopsies in metastatic gastrointestinal cancer to identify candidate therapeutic targets
|
Pérez, L.
|
|
|
29 |
S6 |
p. vi1
|
artikel
|
| 8 |
Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer
|
Guney Eskiler, G.
|
|
|
29 |
S6 |
p. vi23
|
artikel
|
| 9 |
Autotaxin: A possible new biological marker of endometrial cancer
|
de Nola, R.
|
|
|
29 |
S6 |
p. vi1
|
artikel
|
| 10 |
CD62L expression in chronic lymphocytic leukemia patients
|
Elkhouly, E.A.
|
|
|
29 |
S6 |
p. vi5
|
artikel
|
| 11 |
Cell-free circulating BRAF V600 mutations analysis by biochip-based assay and droplet digital PCR in melanoma patients
|
Emelyanova, M.
|
|
|
29 |
S6 |
p. vi2
|
artikel
|
| 12 |
Characterization of the different cell population in primary culture of breast tumor
|
Pattanayak, B.
|
|
|
29 |
S6 |
p. vi16
|
artikel
|
| 13 |
Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors
|
Baraibar Argota, I.
|
|
|
29 |
S6 |
p. vi21-vi22
|
artikel
|
| 14 |
Circulating tumour DNA as an early marker of recurrence and treatment efficacy in ovarian carcinoma, the CIDOC study
|
Sabatier, R.
|
|
|
29 |
S6 |
p. vi3
|
artikel
|
| 15 |
Clinical impact of a comprehensive molecular approach in advanced gynecologic tumors
|
Lefort, F.
|
|
|
29 |
S6 |
p. vi22
|
artikel
|
| 16 |
Clinical impact of using a deep genomic profile in carcinoma of unknown origin
|
Fernandez Díaz, A.
|
|
|
29 |
S6 |
p. vi10
|
artikel
|
| 17 |
Clinical interpretation of lung cancer molecular profiles using rule-based artificial intelligence
|
Tihanyi, D.
|
|
|
29 |
S6 |
p. vi14
|
artikel
|
| 18 |
Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay
|
Remon, J.
|
|
|
29 |
S6 |
p. vi8-vi9
|
artikel
|
| 19 |
Clinical validation and utility of InVision ctDNA in advanced non-small cell lung cancer (NSCLC) patients
|
Remon, J.
|
|
|
29 |
S6 |
p. vi10-vi11
|
artikel
|
| 20 |
Comparing clonality between components of combined hepatocellular carcinoma and cholangiocarcinoma by targeted sequencing
|
Yoon, N.
|
|
|
29 |
S6 |
p. vi27-vi28
|
artikel
|
| 21 |
Comparison of expression of microRNAs which regulate metastasis genes in breast cancer stem cells and primary breast cancer tissues
|
Rahimi, M.
|
|
|
29 |
S6 |
p. vi15
|
artikel
|
| 22 |
Comprehensive analysis for immune profiles of tumor microenvironment in lung adenocarcinomas: Prognostic effect of immunomodulatory molecules
|
Takamochi, K.
|
|
|
29 |
S6 |
p. vi36
|
artikel
|
| 23 |
Computational integrative analysis of identification of potential therapeutic genes and networks in breast cancer
|
Peer Mohammed, M.
|
|
|
29 |
S6 |
p. vi33
|
artikel
|
| 24 |
Correlation between an automated functional assay that predicts targeted agent (TA) sensitivity and the tumor response of the sorafenib treatment evaluated within the MOST clinical trial
|
Tredan, O.
|
|
|
29 |
S6 |
p. vi15-vi16
|
artikel
|
| 25 |
Crosstalk between hesperetin and miR-486-5p in triple-negative breast cancer (TNBC): An approach towards precision medicine
|
Abdallah, R.M.
|
|
|
29 |
S6 |
p. vi28-vi29
|
artikel
|
| 26 |
Customized or randomized trials for relapsed refractory pediatric Burkitt lymphomas? A retrospective analysis of two clinical cases with comprehensive molecular profiling: Possible explanation for different treatment outcomes after similar targeted therapies
|
Polaskova, K.
|
|
|
29 |
S6 |
p. vi31
|
artikel
|
| 27 |
Decreasing telomerase activity of adenocarcinoma cancer cell line (AGS) is associated with different concentrations of sodium selenite and cadmium chloride and selenium l methionine
|
Hosseini-Asl, S.S.
|
|
|
29 |
S6 |
p. vi29-vi30
|
artikel
|
| 28 |
Detection of ALK, RET, ROS1, NTRK1 and MET rearrangements and actionable mutations using next generation sequencing in patients with non-small cell lung cancer
|
Harlé, A.
|
|
|
29 |
S6 |
p. vi12
|
artikel
|
| 29 |
Differences in expression profiling and biomarkers between histological colorectal carcinoma[s] subsets from the serrated pathway
|
Kot, M.M.
|
|
|
29 |
S6 |
p. vi23
|
artikel
|
| 30 |
DNA damage ATR/Chk1 checkpoint signalling increases PD-L1 immune checkpoint activation and its implication for personalised combination therapy
|
Kumar, N.
|
|
|
29 |
S6 |
p. vi18
|
artikel
|
| 31 |
Does the long noncoding RNA HULC act as a sponge or as a downstream target for miR-186 in hepatocellular carcinoma?
|
Habashy, D.A.
|
|
|
29 |
S6 |
p. vi28
|
artikel
|
| 32 |
Drug Index
|
|
|
|
29 |
S6 |
p. vi37
|
artikel
|
| 33 |
Editorial board
|
|
|
|
29 |
S6 |
p. ii-iii
|
artikel
|
| 34 |
EGFR T790M mutation in treatment-naïve tumor samples: Low frequency, evidence for interaction with EGFR TKI-sensitizing mutations and lack of clear predictive value
|
Imyanitov, E.
|
|
|
29 |
S6 |
p. vi4
|
artikel
|
| 35 |
Elevated plasma levels of hTERT mRNA and DNA in patients with gastric cancer in Northwest of Iran
|
Hosseini-Asl, S.S.
|
|
|
29 |
S6 |
p. vi2
|
artikel
|
| 36 |
Emerging role of FAT1 gene in the regulation of oncogenic miRNA 221/222- 3p in glioma
|
Malik, N.
|
|
|
29 |
S6 |
p. vi24
|
artikel
|
| 37 |
EPHA2/MAPK pathway confers acquired resistance of afatinib in gastric cancer
|
Chen, Z.
|
|
|
29 |
S6 |
p. vi27
|
artikel
|
| 38 |
Epigenomics paves a new way to assess potential toxicity and chemotherapeutic response of breast tumours to 5-fluorouracil
|
Strelnikov, V.V.
|
|
|
29 |
S6 |
p. vi12
|
artikel
|
| 39 |
ERBB2 and PI3KCA mutations in endocrine resistant breast cancer (BC)
|
Venturelli, M.
|
|
|
29 |
S6 |
p. vi30
|
artikel
|
| 40 |
Evaluation of the TruSight Tumor 170 (TST170) assay and its value in clinical research
|
Heydt, C.
|
|
|
29 |
S6 |
p. vi7-vi8
|
artikel
|
| 41 |
Evaluation of topoisomerase II, Ki-67 and P53 expression in non-muscle invasive urothelial carcinoma and their clinical significance
|
Elkhouly, E.A.
|
|
|
29 |
S6 |
p. vi4-vi5
|
artikel
|
| 42 |
Experience of 22 patients with ROS mutated lung adenocarcinoma treated with crizotinib at a tertiary care center in India
|
Talreja, V.
|
|
|
29 |
S6 |
p. vi33
|
artikel
|
| 43 |
Expression of erythropoietin receptor variant forms is associated with lymphatic invasion and metastasis formation in breast cancer
|
Rakosy, Z.
|
|
|
29 |
S6 |
p. vi4
|
artikel
|
| 44 |
Expression of HER2-neu, SKP2 and HIF-1 and their role in predicting the response of muscle invasive urothelial carcinoma to bladder- preservation chemotherapy
|
Elkhouly, E.A.
|
|
|
29 |
S6 |
p. vi5
|
artikel
|
| 45 |
First report of ZNF518B gene expression as a prognostic factor in colorectal cancer development: Role in tissue invasiveness
|
Valiente, F.G.
|
|
|
29 |
S6 |
p. vi30
|
artikel
|
| 46 |
FLYWCH1: A novel transcription factor with tumor suppressor activity
|
Almozyan, S.
|
|
|
29 |
S6 |
p. vi22-vi23
|
artikel
|
| 47 |
100,000 Genomes Project: Cancer programme
|
Sosinsky, A.
|
|
|
29 |
S6 |
p. vi7
|
artikel
|
| 48 |
Gli promotes tumor progression and metastasis through regulating EMT in non–small-cell lung cancer
|
Jiang, L.
|
|
|
29 |
S6 |
p. vi24-vi25
|
artikel
|
| 49 |
Glycolytic enzymes lactate dehydrogenase A (LDHA) and phosphofructokinase P (PFKP) are good biomarkers of survival and potential therapeutic targets in cervical cancer
|
Bolaños, L.V.
|
|
|
29 |
S6 |
p. vi33
|
artikel
|
| 50 |
GNMT negatively regulates MAPK pathway and suppresses the growth and metastasis of hepatocellular cancer cells
|
Jiang, S.
|
|
|
29 |
S6 |
p. vi36
|
artikel
|
| 51 |
Head and neck squamous cell carcinoma organoids as a platform for personalized medicine
|
Driehuis, E.
|
|
|
29 |
S6 |
p. vi8
|
artikel
|
| 52 |
Hedgehog pathway influence in the immune escape of tumor cells through PDL-1 modulation
|
Napolitano, F.
|
|
|
29 |
S6 |
p. vi18
|
artikel
|
| 53 |
Identification of resistance mechanisms for EGFR-targeted therapy in head and neck squamous cell carcinoma: Combining whole-exome sequencing and tumour kinase profiling
|
de Pauw, I.
|
|
|
29 |
S6 |
p. vi22
|
artikel
|
| 54 |
IgM anti-glycan antibodies in sera of colorectal cancer patients
|
Tikhonov, A.A.
|
|
|
29 |
S6 |
p. vi12
|
artikel
|
| 55 |
Immune classification of soft tissue sarcoma and its association with molecular characteristics, and clinical outcome
|
Petitprez, F.
|
|
|
29 |
S6 |
p. vi35
|
artikel
|
| 56 |
Impact of HPV DNA and p16 on radical chemo-radiotherapy response in oropharyngeal cancer patients
|
Yadav, P.
|
|
|
29 |
S6 |
p. vi19
|
artikel
|
| 57 |
Implementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE consortium
|
Grist, E.
|
|
|
29 |
S6 |
p. vi10
|
artikel
|
| 58 |
Integrating personalised medicine into the routine cancer diagnostic pathway in Manchester, UK
|
Henry, J.
|
|
|
29 |
S6 |
p. vi8
|
artikel
|
| 59 |
Investigation of the combined action of cisplatin and 6-phosphogluconate dehydrogenase inhibitor on pancreatic and lung cancer cell lines
|
Savenkova, D.V.
|
|
|
29 |
S6 |
p. vi5
|
artikel
|
| 60 |
Involvement of miR-99a in resistance to chemotherapy in triple-negative breast cancer
|
Garrido-Cano, I.
|
|
|
29 |
S6 |
p. vi32
|
artikel
|
| 61 |
Lessons from the routine tumor molecular profiling in Russia
|
Mileyko, V.
|
|
|
29 |
S6 |
p. vi16
|
artikel
|
| 62 |
Leukocyte telomere length is associated with survival and drug resistance in lung adenocarcinoma patients treated with EGFR-TKIs
|
Yang, M.
|
|
|
29 |
S6 |
p. vi9
|
artikel
|
| 63 |
Leukotriene B4 receptors as a therapeutic target for triple-negative breast cancer
|
Kalinkin, A.I.
|
|
|
29 |
S6 |
p. vi26
|
artikel
|
| 64 |
LINE-1 hypomethylation is a specific aberration in human hepatocellular carcinomas and correlates with shorter overall survival and CIMP-phenotypes
|
Anwar, S.L.
|
|
|
29 |
S6 |
p. vi5
|
artikel
|
| 65 |
MATCH-R development of preclinical models from patient with acquired resistance to targeted therapy
|
Bigot, L.
|
|
|
29 |
S6 |
p. vi11
|
artikel
|
| 66 |
Mechanism informs precision: In vivo determinants of response to anti-CTLA-4 antibodies
|
Furness, A.J.S.
|
|
|
29 |
S6 |
p. vi35
|
artikel
|
| 67 |
Microarray based on comparative genomic hybridization reveals new recurrent genetic aberrations in acute myeloid leukemia
|
Prada-Arismendy, J.
|
|
|
29 |
S6 |
p. vi13-vi14
|
artikel
|
| 68 |
miR-4317, a promising player tuning the anti-tumor armamentarium against breast cancer
|
Youness, R.A.
|
|
|
29 |
S6 |
p. vi18-vi19
|
artikel
|
| 69 |
Mir-506-3p synergistically represses breast cancer progression through altering cell cycle regulators
|
Saad El Din, G.
|
|
|
29 |
S6 |
p. vi28
|
artikel
|
| 70 |
Molecular profiling of tumour and ctDNA in a gastrointestinal cancer cohort at an academic cancer centre
|
Rack, S.
|
|
|
29 |
S6 |
p. vi23-vi24
|
artikel
|
| 71 |
Molecular testing of gliomas
|
Konvalinka, D.
|
|
|
29 |
S6 |
p. vi30
|
artikel
|
| 72 |
Molecular treatment stratification in second-line treatment of pancreatic adenocarcinoma: PePaCaKa-001
|
Kordes, M.
|
|
|
29 |
S6 |
p. vi31
|
artikel
|
| 73 |
Muscleblind-like 1 regulates epithelial to mesenchymal transition markers in triple-negative breast cancer
|
Adam Artigues, A.
|
|
|
29 |
S6 |
p. vi32
|
artikel
|
| 74 |
Mutations in TSC1/TSC2 genes are prevalent in sporadic renal angiomyolipoma and insulinoma tumors, supporting their responsiveness to mTOR inhibitors
|
Anoshkin, K.I.
|
|
|
29 |
S6 |
p. vi25
|
artikel
|
| 75 |
Next Generation Sequencing (NGS) and patient pathways: What is the impact on clinical decision?
|
Coquerelle, S.
|
|
|
29 |
S6 |
p. vi14-vi15
|
artikel
|
| 76 |
Next-generation sequencing reveals high intra-individual molecular concordance between primary head and neck tumors and matched local or distant recurrences
|
Martin, N.
|
|
|
29 |
S6 |
p. vi29
|
artikel
|
| 77 |
NGS cfDNA data as a basis for the development of qPCR diagnostic systems
|
Mileyko, V.
|
|
|
29 |
S6 |
p. vi2
|
artikel
|
| 78 |
Novel mechanism of platinum resistance: Rapid selection of pre-existing BRCA1-proficient tumor cells during neoadjuvant chemotherapy (NACT) for ovarian cancer (OC) in BRCA1 germ-line mutation carriers
|
Imyanitov, E.
|
|
|
29 |
S6 |
p. vi4
|
artikel
|
| 79 |
Oncogenes and cancer-associated thrombosis: Is there a rationale for using molecular findings to assess thromboembolic risk in cancer patients?
|
Provenzano, L.
|
|
|
29 |
S6 |
p. vi16-vi17
|
artikel
|
| 80 |
PARP inhibitor (PARPi) monotherapy treatment in non-BRCA and/or non-serous gynaecological cancers
|
Ryan, A.
|
|
|
29 |
S6 |
p. vi34
|
artikel
|
| 81 |
Personalized neoadjuvant strategy in luminal A breast cancer to increase BCS rate (PLATO study)
|
Han, W.
|
|
|
29 |
S6 |
p. vi17
|
artikel
|
| 82 |
Plasma ctDNA mutation anaysis for identification of initial and acquired resistance to HER2-targeted therapy in advanced gastric cancer patients
|
Gaye, E.
|
|
|
29 |
S6 |
p. vi2
|
artikel
|
| 83 |
Plasminogen activator inhibitor-1 promotes immunosuppression in cancer by modulating immune component of tumor microenvironment
|
Yadav, P.
|
|
|
29 |
S6 |
p. vi35-vi36
|
artikel
|
| 84 |
Potential prognostic markers for recurrence and survival in triple-negative breast cancer
|
Havrysh, K.V.
|
|
|
29 |
S6 |
p. vi16
|
artikel
|
| 85 |
PREDMED®, a normalized expression signature of drug targets versus reference tissues aiming at generalizing treatment personalization
|
Verlingue, L.
|
|
|
29 |
S6 |
p. vi9
|
artikel
|
| 86 |
Preliminary results on mechanisms of resistance to ALK inhibitors: A prospective cohort from the MATCH-R study
|
Recondo, G.
|
|
|
29 |
S6 |
p. vi21
|
artikel
|
| 87 |
PREvalence of BRCA mutations and correlations with Demographic and clinical characteristICs in paTients with ovarian, fallopian tube or primary peritoneal cancer in Romania (PREDICT)
|
Cebotaru, C.L.
|
|
|
29 |
S6 |
p. vi34
|
artikel
|
| 88 |
“PRIME Study": Searching for immune biomarkers in advanced castration resistant prostate cancer (CRPC) patients treated with standard therapy
|
Romero-Laorden, N.
|
|
|
29 |
S6 |
p. vi19-vi20
|
artikel
|
| 89 |
Prognostic value of immune gene’s expression in head and neck squamous cell carcinoma patients
|
Lecerf, C.
|
|
|
29 |
S6 |
p. vi29
|
artikel
|
| 90 |
Quantification BCL6 tissue expression using FISH and immunohistochemistry in diffuse large B-cell lymphoma by digital image analysis
|
Kushnarev, V.
|
|
|
29 |
S6 |
p. vi19
|
artikel
|
| 91 |
RANK expression predicts long term outcome in early luminal breast cancer
|
Kassem, L.
|
|
|
29 |
S6 |
p. vi31
|
artikel
|
| 92 |
‘Real world data’ of genomic sequencing for personalised therapy
|
Bergamino, M.S.
|
|
|
29 |
S6 |
p. vi15
|
artikel
|
| 93 |
Regulating rs2278414 (G/A) disease-associated SNP in ZNF350 3’UTR by miR-150-5p: A step towards personalised therapy in breast cancer
|
Fouad, E.H.
|
|
|
29 |
S6 |
p. vi22
|
artikel
|
| 94 |
Representative sequencing: Profiling extreme tumor diversity
|
Litchfield, K.
|
|
|
29 |
S6 |
p. vi7
|
artikel
|
| 95 |
RETROSPHER. ERBB2 amplification detection in the plasma at diagnosis for early high-risk HER2-positive breast cancer
|
Sabatier, R.
|
|
|
29 |
S6 |
p. vi1
|
artikel
|
| 96 |
Role of ATDC gene as a biomarker of doxorubicin response in triple-negative breast cancer
|
Cervera Vidal, R.
|
|
|
29 |
S6 |
p. vi24
|
artikel
|
| 97 |
Role of miR-449 family on doxorubicin-based chemotherapy response in triple-negative breast cancer
|
Tormo Martin, E.
|
|
|
29 |
S6 |
p. vi25
|
artikel
|
| 98 |
RPS6 through the activation of NRF2 causes resistance to antiHER2 drugs in HER2 amplified gastric cancer (GC) models
|
Gambardella, V.
|
|
|
29 |
S6 |
p. vi31-vi32
|
artikel
|
| 99 |
Serum autoantibodies against tumor-associated antigen cyclin D1 represent a potential biomarker of malignancy in well-differentiated thyroid tumors
|
Belousov, P.V.
|
|
|
29 |
S6 |
p. vi14
|
artikel
|
| 100 |
Study of toxicity of the conventional treatments in myeloproliferative neoplasms, based on the functional status of the RUNX1/CBF-BETA/P300/HIPK2 complex
|
Lozano Asencio, C.
|
|
|
29 |
S6 |
p. vi32
|
artikel
|
| 101 |
Synthetic lethal effects of BMN 673 loaded solid lipid nanoparticles on triple-negative breast cancer
|
Guney Eskiler, G.
|
|
|
29 |
S6 |
p. vi25-vi26
|
artikel
|
| 102 |
Table of Contents
|
|
|
|
29 |
S6 |
p. iv
|
artikel
|
| 103 |
Targeting p63 upregulation may prevent the development of MAPK inhibitor resistance in melanoma
|
Borg, T.-M.
|
|
|
29 |
S6 |
p. vi26
|
artikel
|
| 104 |
The clinical impact of miRNA34a and P53 gene expression in colon cancer
|
Gohar, S.F.
|
|
|
29 |
S6 |
p. vi27
|
artikel
|
| 105 |
The effect of the seleno-L-methionin, sodium selenite and cadmium chloride on telomerase activity of chick embryo neural tube cells
|
Akhavan, H.
|
|
|
29 |
S6 |
p. vi33
|
artikel
|
| 106 |
The functional MDM4 genetic variant is associated with clinical outcome of lung adenocarcinoma patients with gefitinib treatment
|
Zhang, N.
|
|
|
29 |
S6 |
p. vi7
|
artikel
|
| 107 |
The reduction of the expression of B-catenin and c-Myc is related to a better outcome in patients with AML
|
Cardona, A.
|
|
|
29 |
S6 |
p. vi26
|
artikel
|
| 108 |
The role of topoisomerase II-α (TOPO IIA) as a predictive factor for response to neoadjuvant anthracycline-based chemotherapy in locally advanced breast cancer
|
Gamea, M.M.
|
|
|
29 |
S6 |
p. vi28
|
artikel
|
| 109 |
TP53 mutations as predictor of response and longer survival under immune checkpoint inhibitors in advanced non-small cell lung cancer
|
Assoun, S.
|
|
|
29 |
S6 |
p. vi19
|
artikel
|
| 110 |
Translational Research Index
|
|
|
|
29 |
S6 |
p. vi38-vi39
|
artikel
|
| 111 |
TRIB3: A new transcriptional target gene of rapalogs, modulating their effects on splicing
|
Stefanovska, B.
|
|
|
29 |
S6 |
p. vi21
|
artikel
|
| 112 |
TRIBE; Tyrosine kinase inhibitor therapy in renal-cell carcinoma: Immune biomarker evaluation
|
Villa, S.
|
|
|
29 |
S6 |
p. vi20
|
artikel
|
| 113 |
TRK wild-type and fusion protein expression in solid tumors: Characterization by immunohistochemistry and in situ hybridization
|
Feng, J.
|
|
|
29 |
S6 |
p. vi27
|
artikel
|
| 114 |
Tumor suppressor P53 gene codon 72 polymorphism and imatinib cytogenetic response in chronic myeloid leukemia
|
Elkhouly, E.A.
|
|
|
29 |
S6 |
p. vi6
|
artikel
|
| 115 |
Wnt-signaling pathway in the cancer stem cells of glioblastoma
|
Bryukhovetskiy, I.S.
|
|
|
29 |
S6 |
p. vi26-vi27
|
artikel
|
Tijdschrift beschrijving